Navigation Links
Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
Date:7/2/2012

TOKYO, July 2, 2012 /PRNewswire/ --

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006. SO-1105 has since been registered in 26 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®.

The clinical study was conducted in a single study centre in Japan, and was designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese adults.

SO-1105, a once daily muco-adhesive buccal tablet containing 50 mg of miconazole administered to the buccal mucosa in 12 healthy volunteers provided a 24-hours sustained high concentration in saliva and on the infection site (upper surface of the tongue). In addition, low plasma concentration indicates that no serious systemic adverse events can be expected. Results from the Phase I study also showed that SO-1105 had a good overall safety profile, and that usability and compliance were good.

SO-1105 has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients' compliance and quality of life.

Shinichi Tamura, CEO of Sosei Group Corporation, commented: "This is an important step forward in development of SO-1105. We will continue our efforts to bring this widely used drug to the Japanese market as quickly as possible."

Notes for Editors:

About Oropharyngeal Candidiasis

Fungal infections of the oral mucosa are most frequently caused by Candida species, with C. albicans being the most common species a
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial ... 2007., Replidyne reported a net loss of $16.9 million ... loss per basic and diluted common share,of $0.63 per share, ... per,basic and diluted common share, for the quarter ended December ...
... SCOTTSDALE, Ariz., Feb. 26 MedPredict Market Research,a ... has published a new report providing critical strategic ... in the market for Rheumatoid,Arthritis (RA) therapies., ... & Analysis:,Rheumatoid Arthritis Q1 2008, MedPredict,s global Thought ...
... Current Radlink Board Member ... Joins Team, ... hardware company that has emerged as an,innovative provider of medical imaging systems ... With nearly 30 years of experience, Dr. Julien is currently director ...
Cached Biology Technology:Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2Renowned Radiologist Peter J. Julien, MD Named Radlink Chief Medical Officer 2
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... Stem cells in bone marrow need to produce hydrogen ... tissue, according to a new study from the Center ... of Dentistry of USC. , Professor Songtao Shi, principal ... sulfide produced by the cells governs the flow of ... cellular signals that results in osteogenesis, or the creation ...
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... Research to be presented at the upcoming annual ... Behavior (SSIB), the foremost society for research into all ... can become dependent on highly palatable foods and engage ... behaviors we observe in drug addicts and those with ...
... The continued growth of cropland and loss of ... the Midwest. A Great Lakes Bioenergy Research Center ... with increased crop pest abundance and insecticide use, ... crops. While the relationship between landscape simplification, ...
... cities can make a significant contribution to carbon storage and, ... authorities and gardeners planted and maintained more trees. The study, ... of Applied Ecology , is the first to quantify how ... of Europe. Using satellite data and information gathered by ...
Cached Biology News:Evidence for 'food addiction' in humans 2Landscape change leads to increased insecticide use in the Midwest 2Plants in cities are an underestimated carbon store 2
... Our Accumix standard is a new ... mode electrospray ionization mass spectrometry. Accumix ... broad mass range coverage for both tuning ... LCQ- and LTQ-MS) and Fourier transform mass ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: